Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

Peer Review reports

Original Submission
29 Jun 2021	Submitted	Original manuscript
8 Jul 2021	Reviewed	Reviewer Report
21 Jul 2021	Reviewed	Reviewer Report
14 Aug 2021	Reviewed	Reviewer Report - Rami Riziq Yousef Abumuaileq
21 Oct 2021	Author responded	Author comments - Ashutosh Wechalekar
Resubmission - Version 2
21 Oct 2021	Submitted	Manuscript version 2
24 Nov 2021	Author responded	Author comments - Ashutosh Wechalekar
Resubmission - Version 3
24 Nov 2021	Submitted	Manuscript version 3
Publishing
26 Nov 2021	Editorially accepted
13 Feb 2022	Article published	10.1186/s12872-021-02407-6

Back to article page